OREANDA-NEWS. September 04, 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that one of its European patents has been validated in Austria, Belgium, France, Germany, Great Britain, Italy, the Netherlands, Portugal, Spain, Sweden and Turkey.

Patent EP 2 343 079 covers the broad use of the company's cell suspension preparation device, ReCell®, and relates to a simple, rapid and cost-effective technique for grafting cells. In particular, the patent covers a device for preparing a suspension of cells using a tissue sample obtained from a donor site.

"This patent is an important addition to our intellectual property estate, which further strengthens Avita's position as a leader in skin repair technology," said Adam Kelliher, Chief Executive Officer of Avita Medical Ltd. "We are pleased that Avita's ownership and inventorship of the ReCell® technology is now recognized in these eleven countries, and believe that the protections it affords represent an important step in our efforts to maximize the value of our proprietary regenerative platform."

Avita technology has thus far been applied to the treatment of chronic wounds, severe burns and skin discoloration.